Biomea Fusion Announces Near Doubling the Percentage of Patients with Durable HbA1c Reduction in the 200 mg Dose Cohorts
December 09, 2023 17:30 ET
|
Biomea Fusion, Inc.
At Week 26, 22 weeks after the last dose of BMF-219, the 200 mg cohorts increased the percentage of patients to approximately 40% with durable HbA1c reduction of 1% or more as compared to the 100 mg...
FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat in Patients with Anemia of Lower Risk Transfusion-Dependent Myelodysplastic Syndromes at American Society of Hematology Annual Meeting
December 09, 2023 17:02 ET
|
FibroGen, Inc.
please call Meichiel Keenan@650-219-6482 with any questions.
Cogent Biosciences Announces Positive Initial Data from Phase 2 SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM)
December 09, 2023 13:30 ET
|
Cogent Biosciences, Inc.
Rapid and ongoing improvement in patient symptoms, with 57% median best improvement on MC-QoL and 78% of patients reporting ≥1 point improvement on PGIS by week 20 100% of bezuclastinib treated...
Corvus Pharmaceuticals Presents New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial
December 09, 2023 12:00 ET
|
Corvus Pharmaceuticals, Inc.
Anti-tumor activity and durability of responses data support advancement of soquelitinib (formerly known as CPI-818) into Phase 3 registrational clinical trial and its potential to address the need...
X4 Pharmaceuticals Announces Presentation of Additional Data from Mavorixafor Phase 2 Trial in Chronic Neutropenia at ASH 2023
December 09, 2023 12:00 ET
|
X4 Pharmaceuticals
Initial data continue to support advancement of mavorixafor into pivotal, global Phase 3 trial in certain chronic neutropenic disorders; company on track to initiate in 1H 2024 X4 expects to...
Allogene Therapeutics Presents Comprehensive Safety Data of Proprietary Lymphodepletion Agent ALLO-647 at the 65th Annual Meeting of the American Society of Hematology
December 09, 2023 12:00 ET
|
Allogene Therapeutics, Inc.
Comprehensive Review of All Patients in the Phase 1 ALPHA/ALPHA2 Trials Demonstrate that Adding Investigational ALLO-647 to Standard Lymphodepletion Can Yield Durable Responses and a Safety Profile...
TScan Therapeutics Presents Initial Phase 1 Clinical Results on TSC-100 and TSC-101 at the 65th American Society of Hematology Annual Meeting and Exposition
December 09, 2023 12:00 ET
|
TScan Therapeutics, Inc.
No relapses have occurred in six of six treatment-arm patients, four with follow-up past six months; one of four control-arm patients relapsed at six months and two others required clinical...
Century Therapeutics Presents Initial Data from CNTY-101 Phase 1 ELiPSE-1 Trial Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion™ Edits
December 09, 2023 12:00 ET
|
Century Therapeutics, Inc.
– Data presented at 65th ASH Annual Meeting show CNTY-101 was generally well tolerated at Dose Level 1 (100 million cells) in a high-risk, heavily pretreated R/R B-cell lymphoma patient – –...
Adaptive Biotechnologies Announces New Data Highlighting the Clinical Relevance of MRD Testing with clonoSEQ® in Patients with Blood Cancers at the 65th ASH Annual Meeting
December 09, 2023 08:30 ET
|
Adaptive Biotechnologies
Treatment adapted studies show the potential for MRD assessment to guide the personalization of blood cancer careNew data demonstrates MRD assessed from blood in multiple myeloma may be an indicator...
Annual Changes to the Nasdaq-100 Index®
December 08, 2023 20:00 ET
|
Nasdaq, Inc.
NEW YORK, Dec. 08, 2023 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced the results of the annual reconstitution of the Nasdaq-100 Index® (Nasdaq: NDX), which will become effective prior...